Expression and clinical significance of cathepsin B and stefin A in laryngeal cancer

Oncology Reports

Volumn 26, Issue 4, 2011, Pages 869-875

  Li, Chunsun ^a   Chen, Liwei ^b   Wang, Jialing ^a   Zhang, Liyong ^d   Tang, Pingzhang ^c   Zhai, Suoqiang ^a   Guo, Weiwei ^a   Yu, Ning ^a   Zhao, Lidong ^a   Liu, Mingbo ^a   Yang, Shiming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cathepsin B; Laryngeal cancer; Prognosis; Stefin A

Indexed keywords

CATHEPSIN B; STEFIN A;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN A; CATHEPSIN B; CYSTATIN A; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TRANSFECTION;

EID: 79960798064     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1344     Document Type: Article

References (29)

1. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: S5054-S5059, 1991.
2. Cairns RA, Khokha R and Hill RP: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 3: 659-671, 2003. (Pubitemid 37236408)
3. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
4. Turk V, Brzin J, Kotnik M, et al: Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens. Biomed Biochim Acta 45: 1375-1384, 1986. (Pubitemid 17018566)
5. Dubin G: Proteinaceous cysteine protease inhibitors. Cell Mol Life Sci 62: 653-669, 2005.
6. Keppler D: Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235: 159-176, 2006.
7. Berdowska I: Cysteine proteases as disease markers. Clin Chim Acta 342: 41-69, 2004.
8. Lah TT, Kokalj-Kunovar M, Strukelj B, et al: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50: 36-44, 1992.
9. Parker BS, Ciocca DR, Bidwell BN, et al: Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol 214: 337-346, 2008. (Pubitemid 351212389)
10. Strojan P, Budihna M, Smid L, et al: Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 1052-1062, 2000. (Pubitemid 30159367)
11. Strojan P, Oblak I, Svetic B, Smid L and Kos J: Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 90: 1961-1968, 2004. (Pubitemid 38746337)
12. Strojan P, Anicin A, Svetic B, Pohar M, Smid L and Kos J: Stefin A and stefin B: markers for prognosis in operable squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 68: 1335-1341, 2007. (Pubitemid 47176795)
13. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M and Rao JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23: 8486-8496, 2004. (Pubitemid 39540799)
14. Tummalapalli P, Spomar D, Gondi CS, et al: RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol 31: 1039-1050, 2007.
15. Hao XP, Pretlow TG, Rao JS and Pretlow TP: Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 61: 8085-8088, 2001. (Pubitemid 33091594)
16. Turk B, Turk D and Turk V: Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477: 98-111, 2000. (Pubitemid 30119895)
17. Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15: 84-89, 2000. (Pubitemid 30195490)
18. Premzl A, Turk V and Kos J: Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J Cell Biochem 97: 1230-1240, 2006.
19. Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dando PM, Ni J and Abrahamson M: Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem 274: 19195-19203, 1999.
20. Sinha AA, Quast BJ, Wilson MJ, et al: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94: 3141-3149, 2002. (Pubitemid 34670497)
21. Nalla AK, Gorantla B, Gondi CS, Lakka SS and Rao JS: Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther 17: 599-613, 2010.
22. Levicar N, Kos J, Blejec A, et al: Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect Prev 26: 42-49, 2002. (Pubitemid 36087181)
23. Strojnik T, Zajc I, Bervar A, et al: Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch 439: R122-R123, 2000.
24. Herszenyi L, Farinati F, Cardin R, et al: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinasetype plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8: 194, 2008.
25. Premzl A, Zavasnik-Bergant V, Turk V and Kos J: Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 283: 206-214, 2003. (Pubitemid 36269026)
26. Krol J, Sato S, Rettenberger P, et al: Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol Chem 384: 1085-1096, 2003. (Pubitemid 37062969)
27. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF and Lah TT: Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 384: 447-455, 2003. (Pubitemid 36527651)
28. Wickramasinghe NS, Nagaraj NS, Vigneswaran N and Zacharias W: Cathepsin B promotes both motility and invasiveness of oral carcinoma cells. Arch Biochem Biophys 436: 187-195, 2005. (Pubitemid 40332438)
29. Pavlova A, Krupa JC, Mort JS, Abrahamson M and Bjork I: Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of his110. FEBS Lett 487: 156-160, 2000. (Pubitemid 32057104)